skitahoe

Would Genentech Be Better Off Left Alone by Roche?

I certainly agree with all you're saying, however it must also be recognized that Roche is putting money in its own pocket by working to move up the price of DNA. It's a win-win proposition for them.

If they should try a higher bid that also gets rejected, their equity value goes up even more, at this point I doubt they'd want the offer accepted. I haven't done the math, but I suspect they've made several hundreds of millions on their books from the initial offer because of the number of shares they currently hold in DNA and the way the offer moved its price up.

BMY did the same thing with IMCL.

Gary